Hyperuricemia, use of antituberculosis drugs, and liver injury: case report
Anti-tuberculous drug can cause idiosyncratic drug-induced liver injury (DILI). Considering the benefit risk, there will discontinuation therapy and rechallenge after symptom resolve. In addition to anti-tuberculosis drugs, liver injury can occur in patients with hyperuricemia. We report a 60-year-o...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Indonesian |
| Published: |
Poltekkes Kemenkes Yogyakarta
2023-08-01
|
| Series: | Jurnal Teknologi Laboratorium |
| Subjects: | |
| Online Access: | https://teknolabjournal.com/index.php/Jtl/article/view/445 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Anti-tuberculous drug can cause idiosyncratic drug-induced liver injury (DILI). Considering the benefit risk, there will discontinuation therapy and rechallenge after symptom resolve. In addition to anti-tuberculosis drugs, liver injury can occur in patients with hyperuricemia. We report a 60-year-old male patient who had just used the initiation phase of OAT for 20 days experiencing hepatotoxic side effects characterized by complaints of nausea and vomiting for one week. Liver function examination results were normal with AST 23 u/L and ALT 9 u/L. OAT administration was temporarily stopped and started gradually with 150 mg rifampicin, 150 mg isoniazid and 500 mg ethambutol. The second day after using OAT again, given the full dose of 300 mg rifampicin, 300 mg isoniazid and 1000 mg ethambutol. The patient's condition improved after this modification of therapy so that therapy with three anti-TB drugs was continued until he was discharged from the hospital. |
|---|---|
| ISSN: | 2338-5634 2580-0191 |